Stem cells for failing livers: does the delivery route matter?
NCT ID NCT06984497
First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time
Summary
Researchers are testing whether human umbilical cord mesenchymal stem cells can help people with end-stage liver disease, and whether the route of delivery changes the outcome. Participants receive the cells either through a peripheral vein or through the hepatic artery. The trial measures survival at 24 weeks and tracks changes in liver disease severity scores. The goal is to learn which delivery method, if either, is safer and more effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- human umbilical cord mesenchymal stem cells
- What this could lead to
- If one delivery route works better, doctors could choose it to help people with end-stage liver disease live longer or improve their liver function scores.
- What could go wrong
- This is a small study of 32 people, so results may not apply broadly. Stem cell therapy for liver disease is still experimental, and participants face risks from the infusion procedure itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 32 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. 18-80 years old \- 2. End-stage liver disease \- 3. Signed informed consent Exclusion Criteria: 1. Tumours of the liver or other organs \- 2. Liver transplantation recipients \- 3. Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases \- 4. Other diseases that may seriously affect the survival \- 5. Human immunodeficiency syndrome \- 6. Interferon or glucocorticoid therapy within 1 year \- 7. Treated for mental illness \- 8. Participation in other clinical trials within 30 days \- 9. Pregnant or breastfeeding subjects \- 10. Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies \- 11. Severe coagulopathy or renal dysfunction \- 12. Other circumstances that are unsuitable for participation in this study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for End-stage liver diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
General Hospital of Northern Theater Command Recruiting
Shenyang, Liaoning, 110840, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.